Compare MIGI & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIGI | INBS |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.3M |
| IPO Year | N/A | N/A |
| Metric | MIGI | INBS |
|---|---|---|
| Price | $4.54 | $11.75 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.3M | ★ 6.6M |
| Earning Date | 11-14-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,587,942.00 | $3,292,042.00 |
| Revenue This Year | N/A | $778.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 3.26 |
| 52 Week Low | $3.95 | $4.03 |
| 52 Week High | $40.00 | $27.50 |
| Indicator | MIGI | INBS |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 75.15 |
| Support Level | $4.35 | $4.03 |
| Resistance Level | $4.90 | $15.25 |
| Average True Range (ATR) | 0.50 | 2.02 |
| MACD | -0.12 | 0.65 |
| Stochastic Oscillator | 29.02 | 67.91 |
Mawson Infrastructure Group Inc is a digital infrastructure provider with diversified operations across Cryptocurrency Mining and Digital Asset Management. Its mission is to build a bridge between the rapidly emerging digital asset industry and traditional capital markets, with a focus on shareholder returns. The Company has three primary businesses: digital currency or Bitcoin self-mining, customer co-location and related services, and energy markets. It operates in a single segment surrounding its digital currency mining operation.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.